Free tool
FAERS Monitor: Isolyte S In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019711 or its brand name (Isolyte S In Plastic Container, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Gluconate). Reports on generic versions are filed under their own applications.
Reports
6
Serious
5
83% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemorrhage intracranial2
- anxiety1
- atrial fibrillation1
- auditory disorder1
- blood glucose increased1
- concomitant disease aggravated1
- convulsion1
- deafness permanent1
- disability1
- discomfort1
- dry eye1
- ear dryness1
- economic problem1
- emotional distress1
- hypotension1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ear dryness | 1 | 33740.6 | 5580.0 | 8,354 |
| deafness permanent | 1 | 17995.0 | 2990.3 | 4,475 |
| auditory disorder | 1 | 2472.9 | 412.9 | 617 |
| concomitant disease aggravated | 1 | 568.1 | 94.9 | 141 |
| haemorrhage intracranial | 2 | 469.0 | 151.2 | 525 |
| economic problem | 1 | 231.3 | 38.6 | 57 |
| disability | 1 | 177.3 | 29.6 | 43 |
| dry eye | 1 | 70.2 | 11.7 | 17 |
| convulsion | 1 | 61.3 | 10.2 | 14 |
| discomfort | 1 | 57.5 | 9.6 | 13 |
| atrial fibrillation | 1 | 36.0 | 6.0 | 8 |
| emotional distress | 1 | 29.0 | 4.8 | 6 |
| blood glucose increased | 1 | 18.6 | 3.1 | 4 |
| hypotension | 1 | 17.5 | 2.9 | 3 |
| anxiety | 1 | 12.3 | 2.1 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.